Blood biomarker study for early lung cancer diagnosis
Official title: Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study
Run by Royal Marsden NHS Foundation Trust · NCT05432739 · Data updated 2026-11-12
This study is testing if certain blood markers can help tell if lung nodules are harmless or cancerous in patients who have had lung cancer before.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 9 sites (Goodmayes, Essex and 8 other locations) |
| Status | Recruiting |
| Started | April 7, 2021 |
| Main results expected | January 1, 2026 |
| Study ends | January 1, 2031 |
| Registry record updated | June 15, 2023 |
| Trial ID | NCT05432739 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 who are under active investigation or surveillance for incidental lung nodules.
✕Probably not a fit
Patients with active or recent malignancies, infections, or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The NIMBLE study is a prospective observational study aimed at evaluating blood biomarkers in patients with lung nodules. It utilizes artificial intelligence and machine learning techniques to analyze data collected during routine patient care. The primary goal is to differentiate between benign and malignant lung nodules, particularly in patients with a history of lung cancer, and to determine whether a nodule represents a recurrence or a new primary cancer. This approach addresses the challenges of incidental lung nodules detected during CT scans, which often lead to unnecessary anxiety and additional testing.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of lung cancer, potentially improving patient outcomes.
How similar studies have gone: Other studies have shown promise in using AI and machine learning for cancer diagnosis, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients under active investigation or surveillance for incidental lung nodules * Age \> 18. Exclusion Criteria: * Active or previous diagnosis of malignancy (within 5 years preceding baseline scan). * Inability to give informed consent. * Active infection (including tuberculosis or fungal infection). * Clinician-suspected or confirmed active or recent COVID-19 infection (less than 4 weeks before CT scan or required blood sampling date).
Where it's running
-
Barking Havering and Redbridge University Hospitals NHS Trust
Goodmayes, Essex, United Kingdom Recruiting -
Calderdale and Huddersfield NHS Foundation Trust
Huddersfield, United Kingdom Recruiting -
Princess Alexandra Hospital
London, United Kingdom Recruiting -
Whittington Health NHS Trust
London, United Kingdom Recruiting -
University College London Hospitals NHS Foundation Trust
London, United Kingdom Recruiting -
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom Recruiting
Show 3 more locations
-
Royal Marsden Hospital
London, United Kingdom Recruiting -
Northumbria NHS Foundation Trust
Newcastle upon Tyne, United Kingdom Recruiting -
Nottinghamshire Healthcare NHS Foundation Trust
Nottingham, United Kingdom Recruiting
Study contacts
- Principal investigator: Richard Lee, Dr — The Royal Marsden Hospitals NHS Trust
- Study coordinator: Sejal Jain
- Email: sejal.jain@rmh.nhs.uk
- Phone: 02078082603
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.